United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - bicalutamide - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - bicalutamide - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - bicalutamide - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

almus pharmaceuticals ltd - bicalutamide - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

crescent pharma ltd - bicalutamide - oral tablet - 50mg

United States - English - NLM (National Library of Medicine)

northstar rxllc - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d 2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see clinical studies ( 14.2)]. bicalutamide is contraindicated in: hypersensitivity bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet's components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. women bicalutamide has no indication for women, and should not be used in this population. pregnancy bicalutamide can cause fetal harm when administered to a pregnant woman. [see use in specific populations (8.1) ]. risk summary bicalutamide is contraindicated for use in pregnant women because it can cause fetal harm. bicalutamide is not indicated for us

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

torrent pharma (uk) ltd - bicalutamide - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - bicalutamide - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

relonchem ltd - bicalutamide - oral tablet - 50mg

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d 2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: - hypersensitivity bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. - women bicalutamide has no indication for women, and should not be used in this population. - pregnancy bicalutamide can cause fetal harm when administered to a pregnant woman [see us